Kari Puolakka
Research Subjects
Kari Puolakka has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Hannu Kautiainen
Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland
9 shared publications - Vappu Rantalaiho
Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
8 shared publications - Tuulikki Sokka
University of Eastern Finland
4 shared publications - Lauri Juhani Virta
Research Department, Social Insurance Institution, Helsinki, Finland
3 shared publications Andras P Keszei
Center for Translational & Clinical Research Aachen (CTC‐A), Uniklinik RWTH Aachen University, Aachen, Germany
2 shared publicationsAnthony D Woolf
Bone and Joint Research Group, Royal Cornwall Hospital, Truro, UK
2 shared publications
Latest Publications
- Open Access
- 23 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (4) , e42726
Patients with recent-onset systemic lupus erythematosus use more antidepressant medication than matched controls: A case–control study
Systemic lupus erythematosus (SLE) is associated with mental health concerns. We evaluated the quantity, frequency, and risk of antidepressant and antipsychotic medication use associated with recent-onset SLE in a case–control study. SLE patients were identified by their drug reimbursement decisions for SLE medication made during January 1, 2000 to December 31, 2014 from the register of the Social Insurance Institution. The study included 1006 SLE cases and 3005 controls. The information about new purchases of the antidepressants and antipsychotics was retrieved from the National Drug Purchase Register starting 1 year before the reimbursement decision (index day [ID]) until 5 years after the ID, death or December 31, 2015. The defined daily dose (DDD) was used to measure the drug consumption. During the 12 months before the ID, the mean daily antidepressant consumption was 62.3 DDDs and 57.9 DDDs ( P < .001) for patients and controls, respectively. The mean antidepressant consumption rose to 87.3/1000/day in patients and 77.4/1000/day in controls ( P < .001) during the 5-year period after the ID. The adjusted hazard ratio for purchasing antidepressants was 1.45 (95% confidence interval: 1.19–1.77; P < .001) for patients compared to controls. No significant difference was found between patients and controls concerning antipsychotics. An increase in antidepressant use was found among SLE cases, suggesting the presence of mood disorders already at the time of SLE diagnosis. No difference was recorded in the use of antipsychotics, indicating the rarity of chronic psychotic disorders needing long-term antipsychotic treatment in SLE.
- 23 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (4) , e42726
Open AccessPatients with recent-onset systemic lupus erythematosus use more antidepressant medication than matched controls: A case–control study
Systemic lupus erythematosus (SLE) is associated with mental health concerns. We evaluated the quantity, frequency, and risk of antidepressant and antipsychotic medication use associated with recent-onset SLE in a case–control study. SLE patients were identified by their drug reimbursement decisions for SLE medication made during January 1, 2000 to December 31, 2014 from the register of the Social Insurance Institution. The study included 1006 SLE cases and 3005 controls. The information about new purchases of the antidepressants and antipsychotics was retrieved from the National Drug Purchase Register starting 1 year before the reimbursement decision (index day [ID]) until 5 years after the ID, death or December 31, 2015. The defined daily dose (DDD) was used to measure the drug consumption. During the 12 months before the ID, the mean daily antidepressant consumption was 62.3 DDDs and 57.9 DDDs ( P < .001) for patients and controls, respectively. The mean antidepressant consumption rose to 87.3/1000/day in patients and 77.4/1000/day in controls ( P < .001) during the 5-year period after the ID. The adjusted hazard ratio for purchasing antidepressants was 1.45 (95% confidence interval: 1.19–1.77; P < .001) for patients compared to controls. No significant difference was found between patients and controls concerning antipsychotics. An increase in antidepressant use was found among SLE cases, suggesting the presence of mood disorders already at the time of SLE diagnosis. No difference was recorded in the use of antipsychotics, indicating the rarity of chronic psychotic disorders needing long-term antipsychotic treatment in SLE.
- Open Access
- 14 March 2025
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 9 (2) , rkaf039
Pain management, prolonged opioid use, initiated anti-rheumatic treatment and psychiatric morbidity in new-onset psoriatic arthritis
Objectives: To explore the use of DMARDs and painkillers in incident PsA patients. Methods: From the Finnish Social Insurance Institution register we collected all adult patients granted a special reimbursement (SR) for DMARDs for PsA from 1 January 2010 to 31 December 2014 (N = 2678). For each case, three general population controls were matched. The purchases of painkillers, antidepressants, anxiolytics and hypnotics were analysed 1 year before and after the index date (ID; the date the SR was granted) and DMARDs at the ID and 1 year before it. Results: The year preceding the ID, 51% of the patients purchased any DMARDs, with 31% being MTX. Nevertheless, on the ID the respective percentages increased to 95% and 71%. PsA patients purchased all painkillers significantly more often than their controls before the ID and the purchases peaked at the ID. After that, the purchases of paracetamol and NSAIDs decreased but those of opioids remained at almost the same level. PsA patients purchased antidepressants and hypnotics more often than their controls. The use of the antidepressants, anxiolytics, hypnotics and opioids before the ID was associated with the risk of prolonged opioid use. Conclusion: A substantial proportion of incident PsA patients are purchasing DMARDs before the ID, which may reflect the difficulty of setting a PsA diagnosis or may represent the treatment of severe skin psoriasis. PsA patients use more painkillers than their matched controls 1 year preceding the diagnosis. Prolonged opioid use is particularly evident among patients using psychiatric medications.
- 14 March 2025
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 9 (2) , rkaf039
Open AccessPain management, prolonged opioid use, initiated anti-rheumatic treatment and psychiatric morbidity in new-onset psoriatic arthritis
Objectives: To explore the use of DMARDs and painkillers in incident PsA patients. Methods: From the Finnish Social Insurance Institution register we collected all adult patients granted a special reimbursement (SR) for DMARDs for PsA from 1 January 2010 to 31 December 2014 (N = 2678). For each case, three general population controls were matched. The purchases of painkillers, antidepressants, anxiolytics and hypnotics were analysed 1 year before and after the index date (ID; the date the SR was granted) and DMARDs at the ID and 1 year before it. Results: The year preceding the ID, 51% of the patients purchased any DMARDs, with 31% being MTX. Nevertheless, on the ID the respective percentages increased to 95% and 71%. PsA patients purchased all painkillers significantly more often than their controls before the ID and the purchases peaked at the ID. After that, the purchases of paracetamol and NSAIDs decreased but those of opioids remained at almost the same level. PsA patients purchased antidepressants and hypnotics more often than their controls. The use of the antidepressants, anxiolytics, hypnotics and opioids before the ID was associated with the risk of prolonged opioid use. Conclusion: A substantial proportion of incident PsA patients are purchasing DMARDs before the ID, which may reflect the difficulty of setting a PsA diagnosis or may represent the treatment of severe skin psoriasis. PsA patients use more painkillers than their matched controls 1 year preceding the diagnosis. Prolonged opioid use is particularly evident among patients using psychiatric medications.
- 2 September 2024
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 53 (5) , 293-294
Keep a closer eye on ‘seronegative rheumatoid arthritis’
- 2 September 2024
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 53 (5) , 293-294
Keep a closer eye on ‘seronegative rheumatoid arthritis’
- Open Access
- 2 April 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (6) , 1101-1109
Pregnancies in patients with systemic lupus erythematosus during 2000–2018 in Finland: a case–control study
Objectives: The aim was to investigate, how pregnancies proceed in patients with systemic lupus erythematosus (SLE) compared to their individually matched population controls. Material and methods: Adult incident SLE patients were identified from the register of new special reimbursement decisions for SLE drugs in 2000–2014. For each patient, 1–3 randomly selected controls from the Population Register Centre were matched. Data regarding pregnancies were obtained from the Finnish Medical Birth Register, Care Register and Register of Congenital Malformations until 2018. The study utilized data from the Drug Purchase Register and educational information from Statistic Finland. Results: A total of 163 deliveries for 103 mothers with SLE and 580 deliveries for 371 population controls were identified. The duration of pregnancies in SLE women was significantly shorter compared to controls (38.9 versus 39.6 weeks). There were more urgent Caesarean Sections. (15% versus 9%) and need for care at neonatal intensive care unit (NICU) (21% versus 11%) among deliveries in SLE mothers. No statistical difference was observed between SLE and control groups in the occurrence of preeclampsia or major congenital malformations. Gestational age was 2.5 weeks shorter when the mother experienced pre-eclampsia. Hydroxychloroquine was purchased by 30% of SLE mothers during pregnancy. Conclusion: The course of pregnancies in Finnish SLE patients seems to be quite moderate compared to controls, and no new safety issues were detected. The low utilization of hydroxychloroquine indicates that the benefits of the drug to pregnancy and disease course are not optimally recognized by specialists treating SLE mothers.
- 2 April 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (6) , 1101-1109
Open AccessPregnancies in patients with systemic lupus erythematosus during 2000–2018 in Finland: a case–control study
Objectives: The aim was to investigate, how pregnancies proceed in patients with systemic lupus erythematosus (SLE) compared to their individually matched population controls. Material and methods: Adult incident SLE patients were identified from the register of new special reimbursement decisions for SLE drugs in 2000–2014. For each patient, 1–3 randomly selected controls from the Population Register Centre were matched. Data regarding pregnancies were obtained from the Finnish Medical Birth Register, Care Register and Register of Congenital Malformations until 2018. The study utilized data from the Drug Purchase Register and educational information from Statistic Finland. Results: A total of 163 deliveries for 103 mothers with SLE and 580 deliveries for 371 population controls were identified. The duration of pregnancies in SLE women was significantly shorter compared to controls (38.9 versus 39.6 weeks). There were more urgent Caesarean Sections. (15% versus 9%) and need for care at neonatal intensive care unit (NICU) (21% versus 11%) among deliveries in SLE mothers. No statistical difference was observed between SLE and control groups in the occurrence of preeclampsia or major congenital malformations. Gestational age was 2.5 weeks shorter when the mother experienced pre-eclampsia. Hydroxychloroquine was purchased by 30% of SLE mothers during pregnancy. Conclusion: The course of pregnancies in Finnish SLE patients seems to be quite moderate compared to controls, and no new safety issues were detected. The low utilization of hydroxychloroquine indicates that the benefits of the drug to pregnancy and disease course are not optimally recognized by specialists treating SLE mothers.
- 1 November 2020
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (11) , 1423-1431
EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries
Objective As part of European League against Rheumatism (EULAR)/European Musculoskeletal Conditions Surveillance and Information Network, 20 user-focused standards of care (SoCs) for rheumatoid arthritis (RA) addressing 16 domains of care were developed. This study aimed to explore gaps in implementation of these SoCs across Europe. Methods Two cross-sectional surveys on the importance, level of and barriers (patients only) to implementation of each SoC (0–10, 10 highest) were designed to be conducted among patients and rheumatologists in 50 European countries. Care gaps were calculated as the difference between the actual and maximum possible score for implementation (ie, 10) multiplied by the care importance score, resulting in care gaps (0–100, maximal gap). Factors associated with the problematic care gaps (ie, gap≥30 and importance≥6 and implementationResults Overall, 26 and 31 countries provided data from 1873 patients and 1131 rheumatologists, respectively. 19 out of 20 SoCs were problematic from the perspectives of more than 20% of patients, while this was true for only 10 SoCs for rheumatologists. Rheumatologists in countries with lower gross domestic product and non-European Union countries were more likely to report problematic gaps in 15 of 20 SoCs, while virtually no differences were observed among patients. Lack of relevance of some SoCs (71%) and limited time of professionals (66%) were the most frequent implementation barriers identified by patients. Conclusions Many problematic gaps were reported across several essential aspects of RA care. More efforts need to be devoted to implementation of EULAR SoCs.
- 1 November 2020
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (11) , 1423-1431
EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries
Objective As part of European League against Rheumatism (EULAR)/European Musculoskeletal Conditions Surveillance and Information Network, 20 user-focused standards of care (SoCs) for rheumatoid arthritis (RA) addressing 16 domains of care were developed. This study aimed to explore gaps in implementation of these SoCs across Europe. Methods Two cross-sectional surveys on the importance, level of and barriers (patients only) to implementation of each SoC (0–10, 10 highest) were designed to be conducted among patients and rheumatologists in 50 European countries. Care gaps were calculated as the difference between the actual and maximum possible score for implementation (ie, 10) multiplied by the care importance score, resulting in care gaps (0–100, maximal gap). Factors associated with the problematic care gaps (ie, gap≥30 and importance≥6 and implementationResults Overall, 26 and 31 countries provided data from 1873 patients and 1131 rheumatologists, respectively. 19 out of 20 SoCs were problematic from the perspectives of more than 20% of patients, while this was true for only 10 SoCs for rheumatologists. Rheumatologists in countries with lower gross domestic product and non-European Union countries were more likely to report problematic gaps in 15 of 20 SoCs, while virtually no differences were observed among patients. Lack of relevance of some SoCs (71%) and limited time of professionals (66%) were the most frequent implementation barriers identified by patients. Conclusions Many problematic gaps were reported across several essential aspects of RA care. More efforts need to be devoted to implementation of EULAR SoCs.
- 1 November 2019
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 78 (11) , 1472-1479
Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries
Objectives To describe and explore differences in formal regulations around sick leave and work disability (WD) for patients with rheumatoid arthritis (RA), as well as perceptions by rheumatologists and patients on the system’s performance, across European countries. Methods We conducted three cross-sectional surveys in 50 European countries: one on work (re-)integration and social security (SS) system arrangements in case of sick leave and long-term WD due to RA (one rheumatologist per country), and two among approximately 15 rheumatologists and 15 patients per country on perceptions regarding SS arrangements on work participation. Differences in regulations and perceptions were compared across categories defined by gross domestic product (GDP), type of social welfare regime, European Union (EU) membership and country RA WD rates. Results Forty-four (88%) countries provided data on regulations, 33 (75%) on perceptions of rheumatologists (n=539) and 34 (77%) on perceptions of patients (n=719). While large variation was observed across all regulations across countries, no relationship was found between most of regulations or income compensation and GDP, type of SS system or rates of WD. Regarding perceptions, rheumatologists in high GDP and EU-member countries felt less confident in their role in the decision process towards WD (β=−0.5 (95% CI −0.9 to −0.2) and β=−0.5 (95% CI −1.0 to −0.1), respectively). The Scandinavian and Bismarckian system scored best on patients’ and rheumatologists’ perceptions of regulations and system performance. Conclusions There is large heterogeneity in rules and regulations of SS systems across Europe in relation to WD of patients with RA, and it cannot be explained by existing welfare regimes, EU membership or country’s wealth.
- 1 November 2019
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 78 (11) , 1472-1479
Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries
Objectives To describe and explore differences in formal regulations around sick leave and work disability (WD) for patients with rheumatoid arthritis (RA), as well as perceptions by rheumatologists and patients on the system’s performance, across European countries. Methods We conducted three cross-sectional surveys in 50 European countries: one on work (re-)integration and social security (SS) system arrangements in case of sick leave and long-term WD due to RA (one rheumatologist per country), and two among approximately 15 rheumatologists and 15 patients per country on perceptions regarding SS arrangements on work participation. Differences in regulations and perceptions were compared across categories defined by gross domestic product (GDP), type of social welfare regime, European Union (EU) membership and country RA WD rates. Results Forty-four (88%) countries provided data on regulations, 33 (75%) on perceptions of rheumatologists (n=539) and 34 (77%) on perceptions of patients (n=719). While large variation was observed across all regulations across countries, no relationship was found between most of regulations or income compensation and GDP, type of SS system or rates of WD. Regarding perceptions, rheumatologists in high GDP and EU-member countries felt less confident in their role in the decision process towards WD (β=−0.5 (95% CI −0.9 to −0.2) and β=−0.5 (95% CI −1.0 to −0.1), respectively). The Scandinavian and Bismarckian system scored best on patients’ and rheumatologists’ perceptions of regulations and system performance. Conclusions There is large heterogeneity in rules and regulations of SS systems across Europe in relation to WD of patients with RA, and it cannot be explained by existing welfare regimes, EU membership or country’s wealth.
- 15 October 2019
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 47 (8) , 1285-1292
Opioid Use among Patients with Early Inflammatory Arthritides Compared to the General Population
Objective.: To assess to what extent the worldwide opioid epidemic affects Finnish patients with early inflammatory arthritis (IA).Methods.: From the nationwide register maintained by the Social Insurance Institution of Finland, we collected all incident adult patients with newly onset seropositive and seronegative rheumatoid arthritis (RA+ and RA–) and undifferentiated arthritis (UA) between 2010 and 2014. For each case, 3 general population (GP) controls were matched according to age, sex, and place of residence. Drug purchases between 2009 and 2015 were evaluated 1 year before and after the index date (date of IA diagnosis), further dividing this time into 3-month periods.Results.: A total of 12,115 patients (66% women) were identified. At least 1 opioid purchase was done by 23–27% of the patients 1 year before and 15–20% one year after the index date. Relative risk (RR) of opioid purchases compared to GP was highest during the last 3-month time period before the index date [RR 2.81 (95% CI 2.55–3.09), 3.06 (2.68-3.49), and 4.04 (3.51–4.65) for RA+, RA–, and UA, respectively] but decreased after the index date [RR 1.38 (1.23–1.58), 1.91 (1.63–2.24), and 2.51 (2.15–2.93)]. Up to 4% of the patients were longterm users both before and after the diagnosis.Conclusion.: During 2009–15 in Finland, opioid use peaked just before the diagnosis of IA but decreased rapidly after that, suggesting effective disease control, especially in seropositive RA. Further, opioids were used to treat arthritis pain of patients with incident RA and UA less often than previously reported from other countries.
- 15 October 2019
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 47 (8) , 1285-1292
Opioid Use among Patients with Early Inflammatory Arthritides Compared to the General Population
Objective.: To assess to what extent the worldwide opioid epidemic affects Finnish patients with early inflammatory arthritis (IA).Methods.: From the nationwide register maintained by the Social Insurance Institution of Finland, we collected all incident adult patients with newly onset seropositive and seronegative rheumatoid arthritis (RA+ and RA–) and undifferentiated arthritis (UA) between 2010 and 2014. For each case, 3 general population (GP) controls were matched according to age, sex, and place of residence. Drug purchases between 2009 and 2015 were evaluated 1 year before and after the index date (date of IA diagnosis), further dividing this time into 3-month periods.Results.: A total of 12,115 patients (66% women) were identified. At least 1 opioid purchase was done by 23–27% of the patients 1 year before and 15–20% one year after the index date. Relative risk (RR) of opioid purchases compared to GP was highest during the last 3-month time period before the index date [RR 2.81 (95% CI 2.55–3.09), 3.06 (2.68-3.49), and 4.04 (3.51–4.65) for RA+, RA–, and UA, respectively] but decreased after the index date [RR 1.38 (1.23–1.58), 1.91 (1.63–2.24), and 2.51 (2.15–2.93)]. Up to 4% of the patients were longterm users both before and after the diagnosis.Conclusion.: During 2009–15 in Finland, opioid use peaked just before the diagnosis of IA but decreased rapidly after that, suggesting effective disease control, especially in seropositive RA. Further, opioids were used to treat arthritis pain of patients with incident RA and UA less often than previously reported from other countries.
- 29 October 2015
- Published by Oxford University Press (OUP)
Comorbidities of rheumatic disease
All other diseases that coexist with a disease of interest are called comorbidities. Comorbidities in inflammatory rheumatic diseases may be associated with persistent inflammatory activity or disease-related organ damage, or may be related to medications. Lifestyle choices such as smoking or physical inactivity contribute to comorbidity. Patients with rheumatic diseases meet health professionals regularly and are more often tested for osteoporosis or cholesterol levels than individuals without rheumatic disease, which may contribute to a higher prevalence of some comorbidities. Comorbidities can also be unrelated to rheumatic diseases or their treatments. In this chapter, we discuss the impact of comorbidities to the patient. We emphasize the importance to review and manage comorbidities in usual daily rheumatology clinic, to improve outcomes of patients with rheumatic diseases.
- 29 October 2015
- Published by Oxford University Press (OUP)
Comorbidities of rheumatic disease
All other diseases that coexist with a disease of interest are called comorbidities. Comorbidities in inflammatory rheumatic diseases may be associated with persistent inflammatory activity or disease-related organ damage, or may be related to medications. Lifestyle choices such as smoking or physical inactivity contribute to comorbidity. Patients with rheumatic diseases meet health professionals regularly and are more often tested for osteoporosis or cholesterol levels than individuals without rheumatic disease, which may contribute to a higher prevalence of some comorbidities. Comorbidities can also be unrelated to rheumatic diseases or their treatments. In this chapter, we discuss the impact of comorbidities to the patient. We emphasize the importance to review and manage comorbidities in usual daily rheumatology clinic, to improve outcomes of patients with rheumatic diseases.
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 403-404
FRI0061 The Concomitance of Inflammatory Bowel Disease with Incident Rheumatoid Arthritis and Ankylosing Spondylitis in Finland
Background Association between ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) is well established. Some reports have suggested increased concomitance of rheumatoid arthritis (RA) with IBD, as well. Objectives To examine the prevalence of IBD among incident patients with RA and AS in Finland Methods Finland has a general sickness insurance covering the entire population. Patients with certain chronic diseases (e.g., RA, AS IBD, etc.) are entitled to special reimbursement of medications if their condition meets defined criteria. The reimbursement decisions are recorded in the national registry of the Social Insurance Institution. From this registry all incident cases of RA (ICD-10 code M05 for RF/anti-CCP positive and M06 for seronegative RA) and AS (ICD-10 code M45) between 1 Jan 2004 and 31 Dec 2007 were identified. From the same source prevalent cases of IBD (colitis ulcerosa, morbus Crohn; ICD-10 codes K50 and K51) were gathered and any coexistence recorded. Results A total of 7209 incident patients over 17 years of age with RA (68% female, 65% RF positive, age 57±15) and 1436 with AS (40% female, age 38±11) were identified. Of the patients with RA, 35 individuals (0.49%; 95% CI: 0.34 to 0.67), 24 (0.49%) female and 11 (0.47%) male, already had IBD at the index day of reimbursement decision for antirheumatic medication. Age-adjusted rate ratio (RR) of women compared to men was 1.04 (95% CI: 0.50 to 2.19). Compared to the general population, the age and sex–adjusted standardized rate ratio (SRR) was 0.74 (95% CI: 0.51 to 1.03); for RF positive patients it was 0.69 (0.43 to 1.05) and for RF negative ones 0.83 (0.45 to 1.39). Of the incident patients with AS, 29 individuals (2.0%; 95% CI: 1.4 to 2.9), 11 (1.93%) female and 18 male (2.08%), had concomitant IBD. Age-adjusted rate ratio (RR) of women compared to men was 1.07 (95% CI: 0.51 to 2.26). Age-and sex-adjusted SRR was 2.73 (1.83 to 3.92). Conclusions Co-occurrence of incident RA with IBD was not increased compared to the general population. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.5122
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 403-404
FRI0061 The Concomitance of Inflammatory Bowel Disease with Incident Rheumatoid Arthritis and Ankylosing Spondylitis in Finland
Background Association between ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) is well established. Some reports have suggested increased concomitance of rheumatoid arthritis (RA) with IBD, as well. Objectives To examine the prevalence of IBD among incident patients with RA and AS in Finland Methods Finland has a general sickness insurance covering the entire population. Patients with certain chronic diseases (e.g., RA, AS IBD, etc.) are entitled to special reimbursement of medications if their condition meets defined criteria. The reimbursement decisions are recorded in the national registry of the Social Insurance Institution. From this registry all incident cases of RA (ICD-10 code M05 for RF/anti-CCP positive and M06 for seronegative RA) and AS (ICD-10 code M45) between 1 Jan 2004 and 31 Dec 2007 were identified. From the same source prevalent cases of IBD (colitis ulcerosa, morbus Crohn; ICD-10 codes K50 and K51) were gathered and any coexistence recorded. Results A total of 7209 incident patients over 17 years of age with RA (68% female, 65% RF positive, age 57±15) and 1436 with AS (40% female, age 38±11) were identified. Of the patients with RA, 35 individuals (0.49%; 95% CI: 0.34 to 0.67), 24 (0.49%) female and 11 (0.47%) male, already had IBD at the index day of reimbursement decision for antirheumatic medication. Age-adjusted rate ratio (RR) of women compared to men was 1.04 (95% CI: 0.50 to 2.19). Compared to the general population, the age and sex–adjusted standardized rate ratio (SRR) was 0.74 (95% CI: 0.51 to 1.03); for RF positive patients it was 0.69 (0.43 to 1.05) and for RF negative ones 0.83 (0.45 to 1.39). Of the incident patients with AS, 29 individuals (2.0%; 95% CI: 1.4 to 2.9), 11 (1.93%) female and 18 male (2.08%), had concomitant IBD. Age-adjusted rate ratio (RR) of women compared to men was 1.07 (95% CI: 0.51 to 2.26). Age-and sex-adjusted SRR was 2.73 (1.83 to 3.92). Conclusions Co-occurrence of incident RA with IBD was not increased compared to the general population. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.5122
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 85
OP0065 Initial Infliximab is not Cost-Effective in Otherwise Actively Treated Early Rheumatoid Arthritis. the 2-Year Follow-Up Results of the Randomized Clinical Neo-Raco Trial
Background In most early rheumatoid arthritis (RA) patients, early remission and a non-progressive state of disease can be achieved when an initial treatment with a triple combination of disease modifying antirheumatic drugs (DMARDs) and on-demand intraarticular glucocorticoids (ia GCs) is used. However, adding infliximab for the first six months to this treatment halts the otherwise marginal radiographic progression totally and decreases the number of ia GCs needed [1]. Objectives To study, with various clinical outcomes, the cost-effectiveness of adding initial infliximab to a remission-targeted combination treatment with DMARDs in early RA. Methods During the first 2 years, the resource use of all RA-related visits, medications, and ia GCs were collected from the 99 patients with early, DMARD-naïve RA, who, within the NEO-RACo trial, were treated with the triple combination of DMARDs (methotrexate, sulphasalazine, hydroxychloriquine) and prednisolone, and who were randomized to double-blindly receive either infliximab (FIN-RACo+INFL) or placebo (FIN-RACo+PLA) infusions during the first 6 months. The treatment goal was strict remission in all patients; pre-defined treatment modifications and ia GCs were applied in active disease. The unit costs of the utilized resources were obtained from the national list of health care unit costs and other published sources. The incremental costs (ICER) for achieving an additional remission or for having radiographic non-progression at 2 years were assessed. Remission was defined by the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Boolean criteria [2], as well as by the very strict FIN-RACo criteria, which allowed no tender or swollen joints [1]. Radiographic non-progression was defined as nil change in the modified Sharp van der Heijde score from baseline to 2 years. Results The total mean costs of treatment for 2 years were €15,347 for the patients in the FIN-RACo+INFL group and €5,481 for the FIN-RACo+PLA group patients (ratio 2.80, 95% CI: 2.34 to 3.13). The Boolean ACR/EULAR remission was achieved at 2 years by 68% and 63%, the strict FIN-RACo remission by 66% and 53%, and absolute radiographic non-progression by 80% and 53% of these patients, respectively. The 2-year ICER per one additional patient achieving these outcomes by adding infliximab on the FIN-RACo strategy for the first 6 months were €208,577, €76,249, and €36,404, respectively. Conclusions Regardless of the clinical outcome assessed, in early RA, adding a six-month course of infliximab into a targeted treatment with combination DMARDs and prednisolone cannot be considered cost-effective. References Leirisalo-Repo M et al. Ann Rheum Dis 2013;72:851-7. Felson DT et al. Arthritis Rheum 2011;63:573-86. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.3265
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 85
OP0065 Initial Infliximab is not Cost-Effective in Otherwise Actively Treated Early Rheumatoid Arthritis. the 2-Year Follow-Up Results of the Randomized Clinical Neo-Raco Trial
Background In most early rheumatoid arthritis (RA) patients, early remission and a non-progressive state of disease can be achieved when an initial treatment with a triple combination of disease modifying antirheumatic drugs (DMARDs) and on-demand intraarticular glucocorticoids (ia GCs) is used. However, adding infliximab for the first six months to this treatment halts the otherwise marginal radiographic progression totally and decreases the number of ia GCs needed [1]. Objectives To study, with various clinical outcomes, the cost-effectiveness of adding initial infliximab to a remission-targeted combination treatment with DMARDs in early RA. Methods During the first 2 years, the resource use of all RA-related visits, medications, and ia GCs were collected from the 99 patients with early, DMARD-naïve RA, who, within the NEO-RACo trial, were treated with the triple combination of DMARDs (methotrexate, sulphasalazine, hydroxychloriquine) and prednisolone, and who were randomized to double-blindly receive either infliximab (FIN-RACo+INFL) or placebo (FIN-RACo+PLA) infusions during the first 6 months. The treatment goal was strict remission in all patients; pre-defined treatment modifications and ia GCs were applied in active disease. The unit costs of the utilized resources were obtained from the national list of health care unit costs and other published sources. The incremental costs (ICER) for achieving an additional remission or for having radiographic non-progression at 2 years were assessed. Remission was defined by the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Boolean criteria [2], as well as by the very strict FIN-RACo criteria, which allowed no tender or swollen joints [1]. Radiographic non-progression was defined as nil change in the modified Sharp van der Heijde score from baseline to 2 years. Results The total mean costs of treatment for 2 years were €15,347 for the patients in the FIN-RACo+INFL group and €5,481 for the FIN-RACo+PLA group patients (ratio 2.80, 95% CI: 2.34 to 3.13). The Boolean ACR/EULAR remission was achieved at 2 years by 68% and 63%, the strict FIN-RACo remission by 66% and 53%, and absolute radiographic non-progression by 80% and 53% of these patients, respectively. The 2-year ICER per one additional patient achieving these outcomes by adding infliximab on the FIN-RACo strategy for the first 6 months were €208,577, €76,249, and €36,404, respectively. Conclusions Regardless of the clinical outcome assessed, in early RA, adding a six-month course of infliximab into a targeted treatment with combination DMARDs and prednisolone cannot be considered cost-effective. References Leirisalo-Repo M et al. Ann Rheum Dis 2013;72:851-7. Felson DT et al. Arthritis Rheum 2011;63:573-86. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.3265